dcc-3009
·Code: DCC-3009
dcc-3009: sourced relationships with 1 company · 1 clinical trial tracked.
dcc-3009 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect dcc-3009 to DCPH; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could dcc-3009 → DCPH affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Deciphera Pharmaceuticals, Inc. (DCPH) | Phase 1/Phase 2 |
Clinical Trial Registry Records (1)
A Master Protocol for the Multi-cohort, Open-label, Phase 1/2 Study of DCC-3009 in Participants With Gastrointestinal Stromal Tumor (GIST)
Primary endpoint: Number of Participants with Dose-Limiting Toxicities (DLT) (Part 1 Escalation)
Interventionalopen120 targetStarted 2024-12Completion 2028-0510 sites · United StatesDeciphera Pharmaceuticals, LLC
Frequently asked questions
Which companies have sourced relationships with dcc-3009?
dcc-3009 has dated SEC/FDA relationship records for Deciphera Pharmaceuticals, Inc..
How many clinical trials involve dcc-3009?
BioSniper tracks 1 clinical trial involving dcc-3009.